Convulxin (CVX), a C-type snake protein from Crotalus durissus terrificus venom, is the quintessential agonist for studies of the collagen receptor, glycoprotein VI (GPVI) and its role in platelet adhesion to collagens. In this study, CVX, purified from venom, behaves as expected, i.e. it binds to platelet GPVI and recombinant human GPVI, induces platelet aggregation and platelet prothrombinase activity, and binds uniquely to GPVI in ligand blots of SDS-denatured proteins. Nonetheless, we find that CVX has a dual specificity for both GPVI and native but not denatured human GPIb␣. First, CVX binds to human GPIb␣ expressed on the surface of CHO cells. Second, CVX binds weakly to murine platelet GPIb␣ but more strongly to human platelet GPIb␣, as evidenced by comparative binding to wild-type, GPVI(؊/؊), FcR␥ (؊/؊), and human GPIb transgenic mice. Third, the binding of CVX to human GPIb␣ is inhibited by soluble, recombinant human GPVI. Fourth, CVX binding to GPIb␣ is disrupted by phenylalanine substitutions at GPIb␣ tyrosine-276, tyrosine-278, and tyrosine-279, which also disrupts von Willebrand factor and ␣-thrombin binding to GPIb␣. Fifth, CVX binding to GPIb␣ on Chinese hamster ovary cell transfectants is inhibited by function-blocking murine monoclonal anti-GPIb␣ antibodies. Lastly, CVX fails to bind to denatured GPIb␣ in detergent extracts of platelets. Three separate preparations of CVX (two purified by the authors; one obtained commercially) produced equivalent results. These results indicate that CVX exhibits dual specificity for both native GPIb␣ and GPVI. Furthermore, the binding site on GPIb␣ for CVX may be close to that for von Willebrand factor. Therefore, a contribution of GPIb␣ to CVX-induced platelet responses needs to be carefully re-evaluated.
Convulxin (CVX)
1 is a 72-kDa protein from Crotalus durissus terrificus venom that has been shown to bind strongly to the platelet-specific collagen receptor, glycoprotein VI (GPVI) (1, 2) .
The active protein is composed of two disulfide-linked subunits, CVX␣ (13.9 kDa) and CVX␤ (12.6 kDa), which noncovalently assemble into a tridimeric complex (␣ ␤) 3 (3) . Both subunits have been cloned and sequenced and exhibit homology with the carbohydrate recognition domain of C-type lectins (4, 5) .
C-type snake proteins are produced in the venom of numerous true vipers and pit vipers (5) . They can be composed of homodimers or heterodimers, often present in multiples, each subunit exhibiting homology to the carbohydrate recognition domain of C-type lectins. Unlike the C-type lectins, however, the subunits of the heterodimeric C-type proteins, such as CVX, do not retain the mannose or galactose recognition sequences and, thus, no longer bind carbohydrate. The ability to bind calcium is retained and may be critical for their activity.
A number of the C-type viper venom proteins target platelet receptors, including the glycoprotein Ib (GPIb) complex and GPVI. The majority, including alboaggregin A (6) and alboluxin (7) , exhibit dual specificity for these receptors, whereas only CVX and the lesser studied trimucytin (8) bind selectively to GPVI.
CVX is a potent inducer of platelet aggregation in vitro, acting presumably through mechanism(s) that are initiated by its binding to GPVI (1, 2) . The strongest evidence that CVX binds uniquely to GPVI is derived from its selective binding in Western blot assays. CVX binds so selectively to GPVI in detergent-solubilized platelet protein preparations that it can be used to quantitate this receptor (9) within the milieu of total platelet proteins. Naturally, this method would not detect binding that might require a native conformation of a target protein. Conversely, the strongest evidence that GPIb is not involved in CVX-induced platelet activation lies in the failure of numerous inhibitory anti-GPIb antibodies (2) to significantly block its activity. This conclusion relies on the assumption that the epitopes on GPIb that are occupied by von Willebrand factor (VWF) are identical to or sufficiently proximal to epitopes occupied by CVX.
Given these caveats, the unique specificity of CVX for GPVI has not been challenged, and it has become the archetypical GPVI-specific agonist.
During the course of our own studies of the effects of CVX on platelet function, particularly studies using stable, transfected Chinese hamster ovary (CHO) cell lines and receptor-deficient or transgenic mice, we noted a number of results that are inconsistent with a unique specificity of CVX for GPVI. In this report, we summarize our systematic re-evaluation of the specificity of CVX and provide conclusive evidence that CVX binds to the native conformation of human but not mouse GPIb␣. In view of these findings, the exact contribution of GPVI vis-à -vis the GPIb complex to platelet activation by CVX needs to be carefully reinvestigated.
EXPERIMENTAL PROCEDURES

Purification and Labeling of CVX-CVX was purified from
Crotalus durissus terrificus venom (Miami Serpentarium Laboratories, Punta Gorda, FL) as described previously (9) . Briefly, 250 mg of lyophilized venom was dissolved in 8 ml of 300 mM NaCl, 100 mM ammonium formate, pH 3.5 (buffer A) containing the following protease inhibitors: Pefabloc-SC (1 g/ml, Roche Molecular Biochemicals), l-1-chloro-3[4-tosyl-amido]-7-amino-2-heptanone (50 g/ml), N-tosyl-L-phenylalanine chloromethyl ketone (100 g/ml), benzamidine (10 mM), leupeptin (4 M), aprotinin (1 g/ml), 5 mM EDTA, and 0.05% NaN 3 . Insoluble components were removed by centrifugation, and the supernatant was loaded on a column (16 ϫ 1200-mm) packed with Sephacryl S-300HR (Amersham Biosciences) and equilibrated with buffer A. Two-ml fractions were collected at a flow rate of 0.5 ml/min, and each was analyzed by SDS-PAGE followed by silver staining of the gels. Fractions that showed a band at 85 kDa under nonreduced conditions and two bands of 14 and 16 kDa under reduced conditions were further analyzed for their ability to induce platelet aggregation. Before the platelet aggregation assays, each fraction was neutralized with 1/10 volume of 1 M Tris, pH 8.5. Fractions positive by both SDS-PAGE and platelet aggregating activity were pooled, concentrated in a Speed-Vac, and then dialyzed against PBS, pH 7.4, containing 0.05% sodium azide. Purified CVX was made to 2 mM EDTA and kept at 4°C. During the course of these studies, two separate batches of CVX were purified from a single lot of C. durissus venom and are designated CVX.1 and CVX.2. CVX was also obtained commercially from Pentapharm, Ltd. (Basel, Switzerland) and is referred to as CVX.P.
To prepare biotin-conjugated CVX, purified CVX in PBS, pH 7.4, at a concentration of 1 mg/ml was mixed with 1/100 volume of Sulfo-NHS-LC biotin (Molecular Probes) dissolved in Me 2 SO at a concentration of 10 mg/ml to give a final concentration of 0.1 mg/ml. After 2 h incubation at ambient temperature, the mixture was extensively dialyzed against PBS, pH 7.4, containing 0.05% sodium azide to remove free biotin.
Recombinant Soluble Human GPVI-Soluble GPVI cDNA was constructed from full-length GPVI cDNA by PCR using the forward primer BglII-WT containing a 5Ј BglII restriction site (5Ј-AGATCTCAGAGT-GGACCGCTCCCCAAG-3Ј) and the reverse primer XbaI-GP6R containing a 3Ј XbaI restriction site (5Ј-TCTAGAGTTGCCCTTGGTGTAG-TACTG-3Ј). After verifying the nucleotide sequence, the PCR-amplified cDNA was digested with EcoRI and subcloned into the Drosophila expression vector pMT/BiP/V5-His (Invitrogen) at BglII and EcoRI sites to enable expression of the GPVI sequence from glutamine-21 through phenylalanine-223 followed by His 6 . To establish stable Drosophila S2 cell lines expressing soluble GPVI, a selection vector pPac-HygB was developed by inserting the Hygromycin B resistance gene, amplified by PCR from the pREP4 vector (Invitrogen), into the Drosophila expression vector pPac. The GPVI cDNA construct and pPac-HygB were cotransfected into S2 cells at a ratio of 20:1 using the Effectene reagent (Qiagen, Valencia, CA), according to the manufacturer's instructions. Transfected cells were grown for 48 h in the presence of the DNA mixture and then cultured in medium containing 300 g/ml Hygromycin B for 4 weeks. Stable cell lines survived this selection and were transferred to serum-free medium (Invitrogen). Secretion of soluble GPVI into the culture medium was induced by addition of 500 M copper sulfate. His 6 -tagged soluble GPVI was purified from harvested culture supernatants by adsorption/elution from a nickel-nitrilotriacetic acid agarose column (Qiagen), according to the manufacturer's instructions. The presence of purified, soluble GPVI was established by SDS-PAGE and Western blotting. Using biotin-CVX as the detection reagent, purified recombinant GPVI migrates as a single protein band with an MW App of 45,000 under nonreduced conditions.
cDNA Constructs-The cDNAs for GPIb␤ and GPIX were cloned into the tetracycline (Tet)-OFF expression vector, pTRE (Clontech). The cDNA encoding GPIb␣ was cloned into a mammalian expression vector, pCDNA3.1Zeo (Invitrogen). The cDNA encoding GPVI and FcR␥ were cloned into 3.1(ϩ) and pcDNA3.1(ϩ)/myc-His B, respectively. We generated a mutant GPIb␣ 3F , by using the Quick Change Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. GPIb␣ 3F is a mutant in which three tyrosine residues (276, 278, and 279) critical for VWF binding have been replaced with phenylalanines.
CHO Cell Transfectants-CHO cells were maintained in 5% CO 2 and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 0.5 mM nonessential amino acids, and 2 mM L-glutamine (Whittaker Bioproducts, Walkersville, MD). A CHO cell line expressing the Tet-controlled transactivator (CHO-AA8, Tet-Off) was purchased from BD Biosciences Clontech. Transfection of CHO cells was performed using liposome (TransFast, Promega, Madison, WI). A stable CHO cell line was established that expresses human GPIb␤ and human GPIX, cloned into the Tet-OFF expression vector pTRE, and the selection plasmid, pTK/Hyg (CHO:(t␤/IX)). pTK/Hyg facilitates selection of stable transformants with hygromycin (800 g/ml, Invitrogen). Because of pTRE, the presence of Tet (200 ng/ml) represses expression of both GPIb␤ and GPIX, whereas the removal of Tet induces both gene products.
The cell line CHO:(t␤/IX) was transfected with the plasmid pCDNA3.1Zeo in which were cloned the wild-type human GPIb␣ to generate CHO:(t␤/IX)␣ or the mutant GPIb␣ 3F to generate CHO:(t␤/ IX)␣ 3F . In the case of the CHO:VI(t␤/IX)␣ cell, we transfected the cDNA of human wild-type GPIb␣ and GPVI/FCR␥ into the CHO:(t␤/IX) cell. This cell line constitutively expresses GPIb␣ and GPVI/FcR␥, whereas the expression of GPIb␤ and GPIX remains Tet-repressible.
After culture for 10 days in the presence of Zeocin (800 g/ml, Invitrogen), we selected single colonies and further cultured these for 2 weeks to establish stable clones. Surface expression of recombinant GPIb␣ was analyzed by flow cytometry using FITC-LJ-P3 (10) . Clones exhibiting comparable high expression levels were selected. Expression of GPVI was analyzed by Western blotting using LJ6.5.
Mice-C57BL/6J mice are referred to as wild-type. Mice deficient in FcR␥ were kindly provided by Prof. Toshiyuki Takai (Tohoku University, Sendai, Japan). Mice deficient in murine GPIb␣ and having a human GPIb␣ transgene were described previously (11) .
Mice deficient in GPVI were established as described by Kato et al. (12) . A 9-kb HindIII restriction fragment spanning mouse GPVI gene exons I-III was cloned into pBS/KSϪ. Within this subcloned fragment a premature stop codon was created immediately 3Ј to the initiation codon by double-stranded, site-directed mutagenesis using Platinum Pfx DNA polymerase (Stratagene). A unique restriction site was also added 3Ј to the premature stop codon to allow insertion of a phosphoglycerate kinase-neo r cassette (kindly provided by Dr. Richard Hynes, Massachusetts Institute of Technology, Cambridge, MO) within exon 1. The final targeting construct contained 4.5-kb arms, both 5Ј and 3Ј, and the 1.7-kb neo r selectable marker immediately downstream to the initiating Met codon. The targeting vector was linearized with NotI and electroporated into DS2A embryonic stem (ES) cells at the Dartmouth Transgenic Facility (Lebanon, NH). Transfected cells were selected for G418 resistance, and ϳ180 clones were expanded for analysis by Southern blotting. A HincII/HindIII restriction fragment outside the targeting vector sequence was used to probe HincII digests of ES cell DNA. Correct homologous recombination was further confirmed by Southern analysis of XbaI-digested ES cell DNA hybridized with a 1.1-kb fragment containing exons 2 and 3. All probes were labeled by [␣-32 P]dATP using the Prime-It II Random Primer Labeling kit from Stratagene. Three clones with the predicted homologous recombination event were confirmed with additional probes and PCR analysis to validate the correct generation of a GPVI-targeted allele. The positive ES cells were microinjected into C57BL/6J mouse blastocysts and were implanted into pseudopregnant females. Chimeric mice were bred to C57BL/6J black mice to test for germ-line transmission. Two chimeric mice from different ES cells produced germ-line offspring as assessed by coat color transmission. Heterozygous mice were crossed to produce the three genotypes, WT (GPVI ϩ/ϩ ), heterozygous (GPVI ϩ/Ϫ ), and homozygousdeficient (GPVI Ϫ/Ϫ ). Studies comparing the three genotypes, such as tail bleeding times, were performed blindly on littermates from GPVI ϩ/Ϫ ϫ GPVI ϩ/Ϫ crosses before genotype analysis. Flow Cytometry-Three l of whole blood was mixed with 50 l of PBS containing 1 mg/ml of bovine serum albumin (PBS-BSA) and 0.1 g of biotin-CVX. The mixture was gently agitated and then incubated for 15 min at ambient temperature. Two l of streptavidin-phycoerythrin (PE; PharMingen) was then added, and the mixture was gently agitated and incubated for an additional 15 min at ambient temperature. To measure the expression of GPIb␣, 3 l of whole blood were mixed with 1 l of fluorescein isothiocyanate (FITC)-conjugated LJ-P3 diluted in 50 l of PBS-BSA. One ml of PBS was added to each sample mixture just before the FACS assay. Measurements were obtained using a Becton Dickinson FACScan, and the data were reported as geometric mean fluorescence intensity (GMFI). Data analysis was performed using WinMDI 2.8.
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Western Blot-Cells were lysed in buffer containing 50 mM Tris-HCl (pH 7.4) and 1% SDS. Twenty g of protein were separated by SDS-PAGE and transferred electrophoretically onto a Sequi-Blot polyvinyl-idine difluoride membrane (Bio-Rad, Richmond, CA). Nonspecific binding of proteins was blocked by incubation of the membrane for 60 min in a solution of 5% fat-free milk in 10 mM Tris-HCl, pH 7.4, containing 145 mM NaCl (TBS) plus 0.05% (v/v) Tween 20 (TBS-T). The membrane was then incubated with anti-GPVI antibody LJ6.5 (10 g/ml in TBS-T) for 120 min at room temperature. After three subsequent rinses in fresh TBS-T, the membrane was further incubated with a 1:2000 dilution of horseradish peroxidase-conjugated anti-mouse IgG (Jackson ImmunoResearch Laboratories) in TBS-T at room temperature for 60 min. After a final three rinses in TBS-T, bound LJ6.5 visualized by enhanced chemiluminescence (ECL, Amersham Biosciences).
RESULTS
Purification and Characterization of CVX-CVX.1 and CVX.2 used in the present study were purified as described (9) . CVX.1 is the same batch used in studies published previously, where it was shown to induce platelet aggregation in citrated platelet-rich plasma at concentrations Ն20 pM, stimulate platelet prothrombinase activity, and bind exclusively to GPVI (and not at all to GPIb␣) in ligand blot assays of total SDS-denatured platelet proteins (9) . CVX.2, purified more recently, has the same biological properties as CVX.1 but differs slightly in composition (or conformation). In SDS-PAGE, under nonreduced conditions ( Fig. 1 ), higher molecular weight components are visible in the biotinylated CVX.1 preparation that are not present in biotinylated CVX.2 or CVX.P. Although these might represent contaminants, it is more likely that they are additional oligomers of CVX, because only the anticipated ␣ and ␤ subunits of CVX (14 and 16 kDa, respectively) are detected in each preparation after reduction. CVX.1 was prepared more than 2 years before CVX.2 and had been stored at 4°C in 0.05% (w/v) NaN 3 , which may account for a gradual accumulation of larger molecular weight entities. Nonetheless, subsequent studies (see below) would demonstrate that all three CVX preparations have the same specificities.
CVX Binds to Human GPIb␣ Expressed on the Surface of CHO Cells-To confirm the specificity of purified CVX for denatured, recombinant human GPVI and its lack of reactivity with denatured, recombinant human GPIb␣, we used a panel of stable CHO cell transfectants (Table I) . First, a stable CHO cell line was established that expresses human GPIb␤ and human GPIX under the control of Tet-responsive elements (CHO:(t␤ IX)). This cell line was then transfected with either WT human GPIb␣ or mutated human GPIb␣ (GPIb␣ 3F ) to generate CHO: (t␤ IX)␣ and CHO:(t␤ IX)␣ 3F , respectively. Because the surface expression of GPIb␣ depends upon the simultaneous expression of both GPIb␤ and GPIX, addition of Tet represses the expression of the GPIb complex. Using CHO:(t␤/IX), we also established CHO:VI(t␤ IX)␣, in which human GPIb␣, human GPVI, and human FcR␥ were stably cotransfected. In this CHO cell line, expression of GPVI and FcR␥ are constitutive, whereas the expression of the GPIb complex remains controllable by Tet. In each of the subsequent figures depicting flow cytometry results, a single representative experiment is shown. In each case, the results were confirmed in two or more independent experiments.
With these stable transfectants in hand, we compared the binding of biotin-CVX.1 and the GPIb␣-specific murine monoclonal antibody LJ-P3 to CHO:(t␤/IX) and CHO:(t␤/IX)␣ ( Fig.  2A) . Lacking GPIb␣, CHO:(t␤/IX) is not bound by LJ-P3 ( Fig.  2A, upper left panel) or biotin-CVX.1 ( Fig. 2A, lower left panel) either in the absence ( Fig. 2A, dense curve) or presence ( Fig. 2A , thin curve) of Tet. On the other hand, CHO:(t␤/IX)␣, which expresses human GPIb␣ under the control of Tet, is bound by LJ-P3 ( Fig. 2A, upper right panel) and biotin-CVX.1 ( Fig. 2A , lower right panel) in the absence of Tet but not in the presence of Tet. The subtle increase in binding of LJ-P3 to CHO:(t␤/IX)␣ (GMFI, 3.77) compared with CHO:(t␤/IX) (GMFI, 1.73) in the presence of 200 ng/ml of Tet probably reflects a very low level of GPIb␣ surface expression in the absence of the ␤/IX subunits. In the absence of ␤/IX, GPIb␣ can be detected on the surface of transfected CHO cells as a dimer. 3 Next, using CHO:VI(t␤IX)␣, we measured CVX binding to GPVI versus GPIb␣. As shown in Fig. 2B (left panel) , the presence of Tet results in a 9-fold reduction in the binding LJ-P3 to CHO:VI(t␤IX)␣. (GMFI shifts from 22.14 to 2.41 in the presence of Tet.) At the same time, the binding of biotin-CVX decreases by roughly one-half (Fig. 2B, right panel) . No significant change in synthesis of GPVI was observed in the presence or absence of Tet, as determined by Western blot assay with murine monoclonal anti-GPVI antibody LJ6.5 (Fig. 2C ). In the case of CHO:(t␤/IX)␣ (negative control), no GPVI was detected in lysates of cells cultured in the absence of Tet (Fig. 2C, left 3 T. Kanaji, unpublished observation.
FIG. 1. Comparison of purified CVXs by SDS-PAGE.
Two preparations of CVX were purified from snake venom (CVX.1 and CVX.2) as described in "Experimental Procedures," and a third preparation was purchased from Pentapharm (CVX.P). Each was conjugated to biotin and subjected to SDS-PAGE under nonreduced (left) or reduced (right) conditions. Molecular weight markers (MW) are included in the left lane of each panel, with the corresponding molecular weights indicated to the left of the gel. Protein components were detected by either ECL, using streptavidin, or by silver staining. Nonreduced (left): 20 ng of purified biotinylated protein was analyzed in each lane. Each CVX preparation contains a major component (bold arrow to the right of the gel) with an apparent molecular weight of 85,000, consistent with the expected size of CVX. Proteins in the depicted gel were visualized by ECL, a procedure that highlights the presence of the higher molecular weight forms in CVX.1. The MW App of these are roughly 150,000 and 220,000, whereas additional protein remains at the interface of the stacking and resolving gel (top). Comparable minor protein bands are visible in CVX.2 (150,000) and CVX.P (220,000). Identical protein bands are visible after silver staining (not shown), although the higher MW entities are not as obvious. Reduced (right): two aliquots of CVX.1 (left, 20 ng; right, 40 ng) were compared with 40 ng each of CVX.2 and CVX.P. Protein components were detected by silver staining. In each case, only two bands are detected in a tight doublet at the bottom of the gel (two bold arrows to the right of the gel). These are consistent with the expected sizes of the CVX ␣ and ␤ subunits. Identical bands were detected in biotin-labeled products using ECL (not shown). lane). In the case of CHO:VI(t␤/IX)␣, GPVI synthesis is constitutive, and the level of the GPVI band is equivalent in cells cultured in the absence (Fig. 2C, center lane) or presence of 200 ng/ml Tet (Fig. 2C, right lane) . These results suggest that CVX can bind to both human GPVI and human GPIb␣. CVX Binds Closely to the Sequence 276 -279 of GPIb␣-A mutant form of GPIb␣, generated by site-directed mutagenesis, was used to further localize the CVX binding site. In 
GPIb␣
3F , three tyrosine residues (276, 278, and 279) critical for VWF binding (Fig. 3A) have been replaced with phenylalanines (13) . As shown in the figure, the tyrosine 278 and 279 residues are not conserved in the murine VWF sequence.
By flow cytometry (Fig. 3B) , the binding of anti-GPIb␣ (LJ-P3) and biotin-CVX.1 to CHO cells transfected with WT (CHO: (t␤ IX)␣) and mutated human GPIb␣ (CHO:(t␤ IX)␣ 3F ) are compared. Tet-repressible binding of both LJ-P3 (Fig. 3B , upper panels) and biotin-CVX.1 (Fig. 3B, lower panels) is apparent in the case of CHO:(t␤ IX)␣ (Fig. 3B, left) , which expresses the WT human GPIb␣. The expression of the GPIb␣ 3F mutant (Fig. 3B, right ) had no effect on LJ-P3 binding but resulted in a virtual elimination of CVX.1 binding. Previous studies had established that LJ-P3 binds equally well to both GPIb␣ and GPIB␣ 3F . These results indicate that the three tyrosines in the sequence 276 -279 of GPIb␣ are necessary for the binding of CVX. These findings imply that a qualitative defect in the ability of GPIb␣ to bind VWF (as observed in the case of GPIb␣ 3F ) may also negatively influence the binding of CVX. It remains to be determined whether the GPIb␣ sequence 276 -279 is directly involved in the binding of CVX or exerts an important allosteric effect on the binding site. Once again, the specificity of CVX.1 for GPIb␣ was confirmed in each case by the marked decline in binding after cells were incubated in the presence of Tet.
CVX Binding to GPIb␣ Is Inhibited by Function-blocking Anti-GPIb␣ Antibody-Further evidence is consistent with an interpretation that CVX binds close to or at the VWF binding region of GPIb␣. Competition experiments were conducted with the murine monoclonal antibody LJ-Ib1 that inhibits VWF binding to GPIb␣ (Fig. 4) . CVX.1 binding to GPIb␣ expressed by CHO:(t␤ IX)␣ in the absence of Tet is inhibited by function-blocking anti-GPIb␣ antibody LJ-Ib1 (Fig. 4, left  panel) but not by a second anti-GPIb␣ antibody LJ-Ib␣ 1 (Fig.  4, right panel) , which recognizes a sequence distinct from the VWF binding region of GPIb␣. LJ-Ib1 and LJ-Ib␣1 were chosen because of their selective binding to different epitopes on GPIb␣. LJ-Ib1 is a selective inhibitor of VWF binding to GPIb␣ (10), whereas LJ-Ib␣1 is a non-inhibitory antibody that recognizes an epitope within residues 1-237 (10). Together with the (Fig. 5, normal curve) . This indicates that there is dose-dependent, competitive binding of CVX to both GPVI and GPIb␣. On the basis of these results, it is unlikely that the binding of CVX to GPIb␣ is attributable to a protein contaminant in the CVX.1 preparation. It is also obvious that residual binding of CVX occurs despite the addition of a 20-fold molar excess of soluble GPVI. This might reflect a lower affinity of CVX for soluble, recombinant GPVI relative to surface-expressed GPIb␣.
CVX.2 and CVX.P Bind to Both Human GPIb␣ and Human GPVI-
The majority of assays of CVX binding to transfected CHO cells were performed with CVX.1, as outlined above. Subsequent analysis with CVX.2 and CVX.P confirmed a shared specificity for both human GPIb␣ and human GPVI (Fig. 6) . The binding of biotinylated ligands to CHO:(t␤/IX) (Fig. 6, lighter curves) is an index of background binding in each case. Expression of GPIb␣ alone by CHO:(t␤/IX)␣ in the absence of Tet (Fig. 6, upper row, bold curves) results in a significant increase in binding of either biotin-CVX.P (Fig. 6, left) or biotin-CVX.2 (Fig. 6, right) . The expression of human GPVI by CHO:VI(t␤/IX)␣ in the presence of Tet (Fig. 6 , bottom row) results in even greater binding by either CVX.P (Fig. 6 , left) or CVX.2 (Fig. 6, right) . Although it is tempting to make conclusions about the relative affinity of CVX for GPVI versus GPIb␣ based on these findings, such a comparison is not valid, because it is not possible to precisely control the transfection efficiency or expression levels of either receptor. These results provide qualitative confirmation that all three CVX preparations used in this study can bind to both human GPVI and human GPIb␣ expressed by transfected CHO cells in vitro.
CVX Binds to Human GPIb␣ but Not to Murine GPIb␣-The binding of biotin-CVX.2 and biotin-CVX.P to human platelets and murine platelets was next compared by flow cytometry using CVX.2 and CVX.P in three independent experiments (Table II) . Negative control binding is represented by the GMFI in the presence of streptavidin-PE but the absence of biotin-CVX (Table II , "control", left). Statistical p values were obtained by the Student t test. In the case of platelets from GPVI Ϫ/Ϫ or FcR␥Ϫ/Ϫ mice, no binding of CVX.2 was observed, whereas an inexplicable but slight increase in binding of CVX.P was detected, relative to the negative control. Both CVX.2 and CVX.P exhibited a significant increase in binding to WT murine platelets. Interestingly, the binding of both CVX.2 and CVX.P to human platelets is consistently stronger than that observed with murine platelets (35.5 versus 13.2 for CVX.2; 49.7 versus 25.5 for CVX.P). The same is true for CVX.1 (not shown). The presence of the human GPIb␣ transgene in mice that are genetically deficient in endogenous murine GPIb␣ results in platelets that bind more strongly to either CVX.2 or CVX.P compared with platelets from WT mouse (18.4 versus 13.2 for CVX.2; 39.1 versus 25.5 for CVX.P). This 1.4-to 1.9-fold increase in GMFI seen with platelets from the human GPIb␣ transgenic mice relative to platelets from WT mice must be attributable to the binding of CVX to the transgenic human GPIb␣ molecules. Interestingly, the tyrosine triplet in human GPIb␣ that is so important for the binding of CVX (see above) is not present in the murine GPIb␣ sequence (Fig. 3A) (14) . This may account in part for the lower affinity of CVX for murine GPIb␣ relative to human GPIb␣.
DISCUSSION
The conclusion from prior studies that CVX binds exclusively to GPVI and not to GPIb␣ was largely based upon competitive inhibition studies with monoclonal or polyclonal antibodies. Even so, Jandrot-Perrus et al. (2) observed that polyclonal anti-GPVI Fab fragments inhibited no more than 50% of platelet aggregation and secretion induced by 30 -40 pM CVX and no more than 60% of platelet adhesion to CVX. No explanation was offered for the residual platelet adhesiveness or platelet activation that could not be inhibited by these antibodies. In the same study, it was reported that SZ2, a monoclonal antibody with inhibitory activity against GPIb␣, had no effect on CVX binding to platelets, CVX-induced platelet aggregation, or platelet adhesion to CVX, but these data were not shown.
Although SZ2 can block certain GPIb-related platelet functions, it is known to have no effect on shear-dependent VWFGPIb interactions (15) . On the other hand, the function blocking antibody used in our study, LJIb1, does inhibit VWF binding to platelets under high shear stress (16) . These data highlight the fact that SZ2 and LJ1b1 have different inhibitory characteristics, although they bind to similar regions of GPIb␣ and that inhibitory studies using exclusively SZ2 may have underestimated a contribution of GPIb␣.
Polgar et al. (1) were aware of the significant sequence similarity between CVX and other C-type lectins known to bind to GPIb. To exclude the involvement of GPIb, they reported that murine monoclonal antibodies against GPIb (Ib-23, SZ2, and AP1) and echicetin (a C-type lectin specific for GPIb) had no effect on CVX-induced platelet aggregation. However, these data were not shown in that report. They went on to demonstrate that partially reduced/denatured CVX has no effect on ristocetin-induced, VWF-dependent platelet agglutination. Ultimately, the only strong evidence that CVX binds uniquely to GPVI rested on the results of ligand blot assays wherein labeled CVX binds only to GPVI isolated by electrophoresis from SDS-lysates of platelets (1, 2). Although we concur that CVX binds exclusively to GPVI after platelet protein isolation under denaturing conditions, e.g. in the presence of SDS (9), our findings in this study show clearly that CVX can bind only to the native conformation of GPIb␣ and that this reactivity is destroyed when platelet proteins are denatured in SDS.
Interestingly, a close comparison of the binding of CVX.1, CVX.2, and CVX.P to GPIb␣ (compare Figs. 2A and 6) indicates that the binding capacity of CVX.1 is higher relative to that of CVX.2 or CVX.P. Having been prepared and stored for a significantly longer time, CVX.1 had an apparently higher oligomer composition than the other two CVX sources. It is possible that higher multimers of CVX favor binding to GPIb␣ relative to GPVI. At this time, it is not possible to control the oligomer composition of CVX purified from snake venom, and such studies may be facilitated by the engineering of recombinant forms of CVX.
In retrospect, a number of the characteristics of CVX binding (3, 17) need to be interpreted cautiously in view of the multisubunit composition of CVX and the fact that extensive iodination can destroy its activity (5). The two-site hypothesis may reflect heterogeneity within the iodinated CVX preparation, resulting in differences in affinity for GPVI. Alternatively, binding to two distinct receptors may also explain these results. There is precedent for dual specificity of C-type lectins for both GPIb and GPVI. Alboaggregin A from Trimeresurus albolabris was first reported to bind to GPIb but later shown to also bind to GPVI (6) . Curiously, alboaggregin A binds solely to GPVI in ligand blotting of SDS-denatured platelet proteins. A second C-type lectin with dual affinity for GPIb␣ and GPVI is alboluxin, identified in the venom of Trimeresurus albolabris (7) . Another example of the promiscuity of C-type lectins might be the behavior of aggretin, derived from Calloselasma rhodostoma (18) . Aggretin (rhodocytin) was initially reported to bind to the integrin collagen receptor ␣ 2␤1 (19) and later reported to also bind to GPIb (18) . However, more recent studies with genetically engineered murine platelets that lack ␣ 2␤1 and GPVI and were stripped of GPIb by proteolysis challenge these conclusions, showing that none of these receptors is required for platelet activation by rhodocytin (20) . This last observation emphasizes the caution that needs to be used in basing ligand specificity solely on the results of immunocompetition assays.
It has been argued that the failure of CVX to induce FITCfibrinogen binding to FcR␥-deficient mouse platelets (18) confirms earlier conclusions that CVX acts solely via GPVI. Alternatively, this result may support a role for FcR␥ in signal transduction initiated by either GPVI or GPIb␣. In fact, studies with other GPIb␣-specific toxins have raised the possibility of a role for FcR␥ in signal transduction initiated by engagement of the GPIb-IX-V complex. The physical proximity of the GPIb-IX-V complex, Fc␥ RIIA, and FcR␥ has been recorded, and there is evidence for functional interrelationships between these molecules (21, 22) . Cross-linking of the GPIb-IX-V complex and Fc␥ RIIA results in tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif in both Fc␥ RIIA and FcR␥ (21) . This leads to binding and phosphorylation of Syk and the ultimate activation of phospholipase C␥2 and other effector molecules. The binding of VWF to the GPIb-IX-V complex has also been shown to result in phosphorylation of FcR␥ (22) . Finally, FcR␥ has been observed to physically associate with GPIb␣ after platelet stimulation with alboaggregin A, which binds to both GPIb␣ and GPVI (23) . All of these observations are consistent with a functional interplay between GPIb␣, FCR␥, and GPVI. Consequently, FcR␥ may be necessary for signaling initiated by selected GPIb␣ ligands, and the results with the FcR␥-deficient mice suggest that CVX is one such ligand.
Our findings suggest that CVX binds close to or at the VWF binding region of GPIb␣ because: 1) a mutant form of GPIb␣, in which tyrosine residues 276, 278, and 279 are replaced by phenylalanines, exhibits comparable qualitative defects in VWF and CVX binding; and 2) murine monoclonal antibodies, such as LJ-Ib1, that inhibit VWF binding to GPIb␣ also block the binding of CVX. The contribution of the tyrosine-276 -tyrosine-279 sequence to VWF and ␣-thrombin binding was initially reported by Marchese et al. (13) , and the importance of this sequence has been confirmed recently through studies of VWF-dependent adhesion under high shear (24) and by a solution of the GPIb␣ structure (25) . Huizinga et al. (26) reported the crystal structure of the VWF A1-GPIb␣ complex, in which the anionic sulfated region of GPIb␣ does not directly contact the VWF A1 domain (26) .
The VWF binding region (residues 251-279) and ␣-thrombin binding region (residues 271-284) of GPIb␣ partially overlap, sharing the three tyrosine residues 276, 278, and 279, which are known to be normally sulfated (27) . The importance of sulfation is evident from observations that ristocetin-dependent VWF binding to heterologous cells expressing the GPIb complex is partially decreased when sulfation is inhibited (27) . Marchese et al. (13) then showed that the sulfate-free recombinant fragment of GPIb␣ (residues 1-302) exhibits a pronounced reduction in the ability to support botrocetin-induced VWF binding. Any two of the three possible sulfotyrosine residues will support VWF binding, whereas all three are necessary for ␣-thrombin binding. In the GPIb␣ structure (25) , the helical arrangement of this segment permits the three sulfate groups from GPIb␣ residues Tyr-276, Tyr-278, and Tyr-279 to interact with four basic residues on the A1 domain of VWF, Lys-569, Arg-571, Lys-572, and Arg-573. This model supports the reported 1:1 stoichiometry for the GPIb␣-A1 domain interaction. Our findings indicate that CVX binding also depends upon the presence of these three tyrosine residues. Two of these tyrosine residues (Tyr-278 and Tyr-279) in human GPIb␣ are not conserved in mouse GPIb␣ (14) (see Fig. 3A ), which is consistent with our data that CVX binds much more strongly to human GPIb␣ than to mouse GPIb␣.
Multimeric CVX may be able to directly activate platelets by binding to this critical region of the GPIb␣ subunit, whereas ␣␤ dimers of the molecule may represent potential inhibitors of GPIb␣-mediated platelet functions. Studies to address these possibilities are now justified and are currently in progress.
The advantages to be gained by the co-binding of CVX to another receptor, such as GPIb, are clear: 1) The number of GPIb␣ molecules on the platelet surface (25,000 to perhaps 50,000) is at least an order of magnitude greater than the number of GPVI molecules (1,000 -5,000). This facilitates cross-linking of receptor molecules and thus more rapid induction of platelet activation; and 2) cross-linking of two receptors would engage additional signal transduction pathways, possibly involving FcR␥ IIA, and in the case of GPIb␣, the additional array of signal transduction intermediates that are unique to that receptor. In view of the dual specificity of CVX, and because of their critical roles in the initiation of platelet adhesion and primary hemostasis, further exploration of the physiological relevance of cross-talk between GPVI and GPIb␣ is warranted.
